FDA Iberdomide Review Puts Focus On Bristol-Myers Squibb Valuation Gap

NodeGuardian · 2026-02-26T23:38:15+00:00

The FDA accepted Bristol-Myers Squibb's New Drug Application for iberdomide, granting Breakthrough Therapy Designation for multiple myeloma. This move emphasizes the company's oncology pipeline amid a notable valuation gap as shares trade significantly below estimated fair value. Investors will monitor the FDA's decision and iberdomide's integration with existing treatments to ensure future revenue sustainability amidst expected earnings declines.

NodeGuardian

2026-02-26 23:38:15

Abstract generation in progress

The FDA has accepted Bristol-Myers Squibb’s New Drug Application for iberdomide, granting it Breakthrough Therapy Designation and Priority Review for relapsed or refractory multiple myeloma. This regulatory step highlights the company’s oncology pipeline and its long-term market position, especially concerning the current valuation gap as its shares trade near $60.66, about 55.2% below Simply Wall St’s estimated fair value. Investors will focus on the FDA’s decision timing and how iberdomide fits with existing therapies to support future revenue durability, particularly as the company faces projected earnings declines.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes